MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into Or ...

A novel acoustofluidics method enhances intracellular nanoparticle delivery, improving biophysical research and therapeutic ...

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle ...

2025 — Scientists have developed an innovative solar-powered method to transform sewage sludge -- a by-product of wastewater treatment -- into green hydrogen for clean energy and single-cell ...

Investment analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will ...

You can increase white blood cells (WBCs) by taking certain medications and eating immune-boosting foods, like yogurt, lean protein foods, antioxidant-rich vegetables, and more. Maintaining a normal ...

PLYMOUTH MEETING, PA, USA I March 13, 2025 I INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help ...

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.